MINSK, 15 October (BelTA) – Belarusian cancer drug Photolon is undergoing a registration process in the Republic of Korea, Deputy Director General of Management Company of the Belpharmprom Holding Company Viktor Shein told reporters, BelTA has learned.

Belarus expects to increase supplies of medicines to Asia Pacific after the registration of this drug in the Republic of Korea is complete.

The drug developed by Belmedpreparaty has been used at Belarusian hospitals for quite a long time and has proved highly efficient. Photolon is applied for photodynamic therapy of malignant tumors. With the help of targeted drug delivery, it concentrates in the diseased tissue without circulating throughout the body.

“Although the Republic of Korea has a broad lineup of its own drugs, it has been conducting clinical tests of this medication in its region for several years already,” Viktor Shein said.

At the same time he noted that promotion of medicines on foreign markets is a cost-intensive thing.